Valuation: GENFIT

Market Cap 700M 806M 650M 600M 1.13B 76.98B 1.15B 7.7B 3.01B 38.23B 3.03B 2.96B 129B P/E 2026 *
36.1x
P/E 2027 * 93x
Enterprise Value 649M 747M 603M 556M 1.05B 71.36B 1.07B 7.14B 2.79B 35.44B 2.81B 2.75B 119B EV / Sales 2026 *
6.48x
EV / Sales 2027 * 5.11x
Free-Float
86.88%
Yield 2026 *
-
Yield 2027 * -
1 day+3.36%
Current month+56.75%
1 month+56.75%
3 months+49.24%
6 months+160.46%
Current year+157.28%
1 month 13.14
Extreme 13.14
13.7
Current year 5.2
Extreme 5.205
13.7
1 year 3.19
Extreme 3.19
13.7
3 years 3.19
Extreme 3.19
13.7
5 years 3.19
Extreme 3.19
13.7
10 years 3.19
Extreme 3.19
13.7
Manager TitleAgeSince
Chief Executive Officer 58 2019-09-15
Director of Finance/CFO 52 2021-04-21
Chief Tech/Sci/R&D Officer - 2025-11-26
Director TitleAgeSince
Chairman 70 2017-06-15
Director/Board Member 54 1999-09-14
Director/Board Member 58 2017-06-15
Change 5-day change 1-year change 3-year change Capi.($)
+3.01%0.00% - - 773M
-0.80%+5.16%-0.70%+12.87% 48.95B
-1.80%+14.78%+24.24%+6.35% 40.75B
+2.67%+1.48%+417.47%+629.68% 38.46B
-11.33%-1.50%+7.31%+50.26% 36.38B
+5.56%+11.70%+11.64%+51.50% 28.45B
-1.99%-2.11% - - 16.62B
-4.22%-4.37%+32.34%+128.84% 16.33B
-10.09%-3.51%-9.45%-34.63% 13.65B
-0.06%-2.81%+3.16%+10.08% 13.56B
Average -0.13%+6.06%+60.75%+106.87% 28.13B
Weighted average by Cap. +0.06%+7.20%+76.31%+127.55%

Financials

2026 *2027 *
Net sales 100M 115M 93.04M 85.81M 162M 11.01B 165M 1.1B 431M 5.47B 433M 424M 18.39B 124M 143M 115M 106M 200M 13.63B 204M 1.36B 534M 6.77B 536M 525M 22.77B
Net income 22.88M 26.34M 21.24M 19.59M 36.91M 2.51B 37.58M 252M 98.48M 1.25B 98.91M 96.75M 4.2B 6.8M 7.83M 6.31M 5.82M 10.97M 747M 11.17M 74.76M 29.27M 371M 29.4M 28.76M 1.25B
Net Debt -51.12M -58.85M -47.47M -43.78M -82.46M -5.62B -83.96M -562M -220M -2.79B -221M -216M -9.38B -66.17M -76.18M -61.45M -56.67M -107M -7.27B -109M -727M -285M -3.61B -286M -280M -12.15B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.58EUR
Average target price
15.90EUR
Spread / Average Target
+17.08%

Quarterly revenue - Rate of surprise